Slow initial uptake of Novo Nordisk's Wegovy likely in Japan, says analyst

28 July 2023

As the first obesity drug to be approved in Japan in the last three decades, Danish diabetes giant Novo Nordisk’s (NOV: N) Wegovy (semaglutide) is expected to bring a substantial shift in the treatment approach.

However, amidst the ongoing supply shortage of the drug leading to delayed launches in various markets, including Japan, Wegovy’s market success is likely to be delayed in the country, says and analytics company GlobalData.

In March 2023, Japan’s Ministry of Health and Labor Welfare (MHLW) approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist Wegovy for obesity. Even though other GLP-1 agonists are currently available for obesity treatment in Japan, they are only used for off-label treatment. These are Eli Lilly’s (NYSE: LLY) Mounjaro (tirzepatide), and Novo Nordisk’s diabetes drugs Ozempic (semaglutide), Victoza (liraglutide), and Rybelsus (semaglutide)).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK